Adrian Divittorio, MD
Pulmonary Disease · Mobile, ALNPI 1720164130
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $67,645 of the $99,944 with a category attached, or 67.7%. 40 manufacturers reported payments, led by Boehringer Ingelheim at 40.7% of the total. Reporting peaked in 2022 at $25,702 and has fallen 85.8% since, to $3,657 in 2025. Among pulmonary disease clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,358 payments — averaging $73.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$41K
- Actelion Pharmaceuticals US, Inc.$34K
- Intuitive Surgical$9K
- AstraZeneca$3K
- GSK$3K
- Jazz Pharmaceuticals Inc.$1K
- plus $9K from 34 others
Across 17 payments — averaging $6602.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$111K
- Novartis$981
What the payments were for
- Speaking & faculty fees$67,64568%
- Travel & lodging$2,7223%
- Food & beverage$22,76923%
- Education$6,8077%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$99,944 in reported general payments places this provider in the 95th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 135 | $1,706,413 |
| UptraviSelexipag | 58 | $1,231,920 |
| OfevNintedanib Esylate | 32 | $437,729 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 12 | $179,685 |
| WakixPitolisant Hcl | 11 | $154,408 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 170 | $137,668 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 130 | $91,759 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $78,835 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 114 | $67,062 |
| Breo ElliptaFluticasone/Vilanterol | 125 | $60,827 |
| Spiriva RespimatTiotropium Bromide | 30 | $25,772 |
| EliquisApixaban | 27 | $17,108 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $12,193 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $11,989 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 270 | $9,344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $33,865 | $2,938,333193 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $40,634 | $539,599194 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $2,985 | $210,484316 claims |
| Insmed, Inc.Arikayce | $1,300 | $179,68512 claims |
| Harmony Biosciences LLCWakix | $637 | $154,40811 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,113 | $103,952172 claims |
| Grifols USA, LLCProlastin C | $479 | $78,83511 claims |
| PfizerEliquis | $147 | $17,10827 claims |
| Johnson & JohnsonXarelto | $471 | $8,15213 claims |
| MerckBelsomra | $369 | $6,80717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Mobile
- Peter LutzMobile$63K
- Virginia RadcliffMobile$23K
- Johnson HaynesMobile$21K
- Cynthia CrowderMobile$20K
- Philip AlmaloufMobile$14K
- Campbell SindelMobile$14K
- Chibuzo OdigweMobile$14K
- Caesar AgaganMobile$11K
- James DeanMobile$10K
- Maher SahawnehMobile$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.